Top Ten most popular articles on Pharmafile.com this week
pharmafile | June 26, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | COVID-19, coronavirus, top 10
The news this week centres on the pandemic in Europe, with the Independent SAGE group are warning that it is not safe to relax social distancing rules for indoor settings in England, while Germany’s coronavirus R number has drastically increased.
In non-COVID-19 news, Florida state regulators have gained approval to release 750 million genetically modified mosquitoes across the state to reduce the spread of the diseases they carry, while the UK Home Office has announced that the drug Epidyolex (cannabidiol) has been reclassified as a Schedule 5 drug, a move from a Schedule 2 substance under the Misuse of Drugs Regulation 2001.
1. NIH ordered to cancel coronavirus research funding by White House, Dr Fauci tells Congress
The National Institutes of Health had its funding cut from a research project into bat coronavirus, according its Director Dr Anthony Fauci.
2. SAGE group warns it is not safe to relax social distancing rules across Britain
The Independent SAGE group has warned that it is not safe to relax social distancing rules for indoor settings, after the government’s expected proposal to reduce it to just 1 metre.
3. EU reportedly in talks with J&J to secure doses of its COVID-19 vaccine
It has been reported that the European Union is currently negotiating a deal with pharma giant Johnson & Johnson to reserve or buy upfront the COVID-19 vaccine the latter currently has in development.
4. Boehringer withdraws its £700m investment in Hikma Pharmaceuticals
Boehringer has revealed that it intends to withdraw its investment from Hikma Pharmaceuticals, with the company poised to sell 28 million shares to the value of around £70 million to institutional investors.
Florida state regulators have gained approval to release 750 million genetically modified mosquitoes across the state to reduce the spread of the diseases they carry.
6. AstraZeneca continues to ramp up COVID-19 vaccine production with new CMO partnership
AstraZeneca has continued to build its manufacturing capacity to deliver its COVID-19 vaccine candidate, developed in partnership with the University of Oxford and currently being tested in human trials across a number of trials across the UK, with its latest partnership signed with Scottish firm Symbiosis Pharmaceutical Services.
7. Study launched to assess if asthma treatment ciclesonide can treat COVID-19
Researchers at the University of Buffalo have launched a study to see if the steroid treatment ciclesonide could be effective in treating the coronavirus.
8. Germany’s infection rate rapidly rises as world sees its largest daily increase in COVID-19 cases
Germany’s coronavirus R number has drastically increased while the world faced its largest increase in cases since the pandemic began.
Eli Lilly has shared new phase 3 data on Verzenio (abemaciclib), in combination with endocrine therapy (ET) following surgery, showing the combo met its main goal in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer.
10. UK Home office reclassifies Epidyolex as a Schedule 5 drug
The Home Office has announced that the drug Epidyolex (cannabidiol) has been reclassified as a Schedule 5 drug, a move from a Schedule 2 substance under the Misuse of Drugs Regulation 2001.
Related Content
Gilead’s Veklury recommended by NICE for COVID-19 treatment
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …
